Results
1 -
10 of
21Phospholipases in Cardiovascular Disease, Phospholipases in Health and Disease Differential effects of sPLA2-GV and GX on cellular proliferation and lipid accumulation in HT29 colon cancer cells, Molecular and Cellular Biochemistry Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial, Cardiovascular Drugs and Therapy Articles You May Have Missed, Journal of Medical Toxicology Varespladib trial terminated, increased MI risk, Reactions Weekly Secretory phospholipase A2: A multifaceted family of proatherogenic enzymes, Current Cardiology Reports Geneticsu2014Current and Future Role in the Prevention and Management of Coronary Artery Disease, Current Atherosclerosis Reports Using genetic variation for establishing causality of cardiovascular risk factors: overcoming confounding and reverse causality, Netherlands Heart Journal Group X secreted phospholipase A2 induces lipid droplet formation and prolongs breast cancer cell survival, Molecular Cancer Suppressive effect of secretory phospholipase A2inhibitory peptide on interleukin-1??-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice, Arthritis Research & Therapy